<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-19</startDate>
            <endDate>2026-10-19</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2026-10-19</startDate>
            <endDate>2026-10-19</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">S-8</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0000906709</dei:EntityCentralIndexKey>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_004">false</ffd:PrevslyPdFlg>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_005" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_006">N/A</ffd:OffsetTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">S-8</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">Nektar Therapeutics</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_009">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_010">Common Stock, $0.0001 par value per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_1" id="fee_011">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_1"
      decimals="0"
      id="fee_012"
      unitRef="shares">250000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_013"
      unitRef="USD">36.83</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="USD">9207500.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="pure">0.000087</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_016"
      unitRef="USD">801.06</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_017"
      unitRef="USD">9207500.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_018"
      unitRef="USD">801.06</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_019"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_020"
      unitRef="USD">801.06</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_021">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;), which become issuable under the Nektar Therapeutics 2025 Inducement Plan, as amended, (the &#x201c;Plan&#x201d;) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant&#x2019;s outstanding shares of common stock.&lt;br/&gt;&lt;br/&gt;The amount to be registered represents 250,000 additional shares of Common Stock issuable under the Plan, pursuant to an amendment approved by the Board of Directors of the Registrant on September 23, 2026.&lt;br/&gt;&lt;br/&gt;The proposed maximum offering price per unit is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act on the basis of the average of the high and low sales prices of the Common Stock as reported on the Nasdaq Capital Market on October 16, 2026.</ffd:OfferingNote>
</xbrl>
